Last reviewed · How we verify
Azopt (BRINZOLAMIDE)
Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion.
Azopt (Brinzolamide) is a small molecule carbonic anhydrase inhibitor developed by Alcon Pharm Ltd and currently owned by Sandoz. It targets carbonic anhydrase 2 to treat ocular hypertension and open-angle glaucoma. Azopt is a generic medication, off-patent since there are no active Orange Book patents. It is used to reduce intraocular pressure in patients with glaucoma. As a carbonic anhydrase inhibitor, Azopt works by blocking the enzyme responsible for producing aqueous humor in the eye, thereby reducing pressure.
At a glance
| Generic name | BRINZOLAMIDE |
|---|---|
| Sponsor | Novartis |
| Drug class | Carbonic Anhydrase Inhibitor [EPC] |
| Target | carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1998 |
Mechanism of action
Brinzolamide works by inhibiting carbonic anhydrase II, an enzyme that helps form bicarbonate ions. By slowing this process, it reduces the production of aqueous humor in the eye, leading to lower intraocular pressure (IOP). This is important because elevated IOP is a key risk factor for optic nerve damage and glaucoma.
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- blurred vision
- bitter, sour, or unusual taste
Key clinical trials
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG) (PHASE4)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE3)
- Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azopt CI brief — competitive landscape report
- Azopt updates RSS · CI watch RSS
- Novartis portfolio CI